Saturday
10.05.2024
4:25 PM
Login form
Search
Calendar
«  March 2024  »
SuMoTuWeThFrSa
     12
3456789
10111213141516
17181920212223
24252627282930
31
Entries archive

My site

Main » 2024 » March » 16

NEW YORK - Friday, 15. March 2024
(BUSINESS WIRE) -- DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a Non-dealer Committee Member of the Determinations Committee for the relevant region.

Parties wishing to apply for such a position should carefully review and submit an executed Non-dealer Committee Participation Letter by 5pm (New York time) on Wednesday, March 20, 2024.

For more information on the process and to download the form of the Non-dealer Committee Participation Letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-committees/constitution-of-the-determinations-committees/.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240315301830/en/


Permalink
https://www.aetoswire.com/en/news/1503202438283
Contacts
Press Inquiries:
orlando.figueroa@citadelspv.com

  ... Read more »

Views: 95 | Added by: africa-live | Date: 03.16.2024 | Comments (0)

Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy

Approval represents the first indication in the U.S. for TEVIMBRA

 

(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in the second half of 2024.

“Today’s FDA approval of TEVIMBRA for patients with ESCC who have previously received chemotherapy, along with its ongoing review of our BLA for first-line ESCC patients, represents a significant step in our commitment to bringing th ... Read more »

Views: 88 | Added by: africa-live | Date: 03.16.2024 | Comments (0)

TAIPEI, Taiwan - Friday, 15. March 2024

The winning products exemplify Posiflex’s innovation-driven entrepreneurship and customer-first ethos

 

(BUSINESS WIRE)--Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce that its Haydn ZT Series - the industry's first clamshell POS terminal with a patented modular design and exceptional serviceability - and its Gen9 Base, which integrates a thermal printer and power supply for maximum space efficiency, have been awarded the iF DESIGN AWARD 2024 in the discipline of Product in the Public/Retail category by the Hannover-based iF International Forum Design GmbH, which is one of the most coveted accolades in the world of design.

The Posiflex Haydn ZT Series and Gen9 Base stood out from a field of nearly 11,000 entries from 72 countries, impressing the 132-strong jury of independent experts from around the world with ... Read more »

Views: 92 | Added by: africa-live | Date: 03.16.2024 | Comments (0)